サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1650989

細胞治療の世界市場

Cell Therapy

出版日
ページ情報
英文 263 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
細胞治療の世界市場
出版日: 2025年02月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 263 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

細胞治療の世界市場は2030年までに421億米ドルに達する見込み

2024年に191億米ドルと推定される細胞治療の世界市場は、分析期間2024-2030年にCAGR 14.1％で成長し、2030年には421億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである同種異系細胞治療は、CAGR 12.8％を記録し、分析期間終了までに234億米ドルに達すると予測されています。自家細胞治療セグメントの成長率は、分析期間中CAGR 15.8％と推定されます。

米国市場は53億米ドルと推定、中国はCAGR13.5％で成長予測

米国の細胞治療市場は、2024年に53億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに65億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.1％と11.9％と予測されています。欧州では、ドイツがCAGR 10.3%で成長すると予測されています。

世界の細胞治療市場- 主要動向と促進要因のまとめ

細胞治療が現代医療のゲームチェンジャーとなる理由とは？

細胞治療は、がん、自己免疫疾患、退行性疾患を含む様々な疾患に対する革新的な解決策を提供し、損傷した組織を治療・修復するために身体自身の細胞を使用することにより、医療分野を劇的に再形成しています。症状を抑えることに重点を置く従来の治療法とは異なり、細胞治療は、特定の生物学的メカニズムを標的とするよう操作したり採取したりできる生きた細胞を利用することで、病気の根本原因に対処することを目指しています。例えば、CAR-T療法は腫瘍学において画期的なもので、患者のT細胞を遺伝子工学的に操作し、がん細胞を探し出して破壊します。この治療法は、ある種の血液がんの治療ですでに目覚ましい成功を収めており、他のがん種にも拡大しつつあります。再生医療では、心臓病、神経変性疾患、糖尿病などで損傷した組織を修復するために幹細胞が使われています。これらの治療は、個別化治療における大きな飛躍を意味し、かつては治療不可能と考えられていた病気の患者に希望を与えるものです。研究が進むにつれ、細胞治療は、患者固有の遺伝子や細胞構成に沿ったオーダーメイド治療を提供する、個別化医療の未来の中心的な柱となりつつあります。

細胞治療は複雑な疾患の治療法をどのように変えるのか？

細胞治療は、従来の治療法に反応しない複雑な疾患の治療に不可欠であり、治療介入の新たな道を提供します。腫瘍学の分野では、CAR-T療法のような細胞ベースの治療が、患者自身の免疫細胞を使ってがん細胞を標的にして殺すことにより、がん治療に革命をもたらしました。この高度に個別化された治療アプローチは、白血病やリンパ腫などのがん、特に従来の化学療法や放射線療法に反応しなかった患者の治療に大きな成功を示しています。腫瘍学にとどまらず、細胞治療は多発性硬化症や関節リウマチのような自己免疫疾患の管理においても飛躍的な進歩を遂げつつあり、そこでは免疫系を調節・再プログラムし、有害な炎症反応を抑えるのに役立っています。再生医療では、心不全、脊髄損傷、神経変性疾患などの治療法の可能性を提供するため、損傷した組織の機能を回復させる幹細胞治療が開発されています。これらの治療法は、組織を修復するだけでなく、病気の原因となる根本的な細胞の欠陥に対処することで、長期的、場合によっては永久的な解決策を提供することを目的としています。細胞治療は、単に症状を治療するだけでなく、細胞レベルで損傷した組織を置き換えたり回復させたりすることができるため、複雑で慢性的な、以前は治療不可能であった疾患に対する画期的な治療法となります。

技術の進歩はどのように細胞治療のイノベーションを促進しているのでしょうか？

技術の進歩は、細胞治療の進歩を急速に加速し、様々な疾患に対してより効果的で、スケーラブルで、利用しやすいものにしています。特にCRISPR-Cas9を用いた遺伝子編集は、治療能力を高めるために細胞を正確に改変することを可能にします。これはCAR-T療法に革命をもたらし、潜在的な副作用を抑えつつ、特定のがん細胞を標的にする効果の高いT細胞を作り出すことを可能にしました。遺伝子工学だけでなく、バイオプロセスやオートメーションの進歩により、制御された環境で大量の治療用細胞を生産することが可能になっています。さらに、凍結保存の改善により、治療用細胞の保存と輸送が容易になり、長距離・長期間にわたって生存性を維持できるようになった。さらに、人工知能（AI）や機械学習が開発に組み込まれ、製造プロセスの最適化、患者の反応予測、治療成績の向上に役立っています。こうした技術革新は、細胞治療の精度と効率を高めるだけでなく、希少な遺伝性疾患から加齢に関連する疾患まで、より幅広い疾患の治療に応用されつつあります。

細胞治療市場の成長を促進している要因は？

細胞治療市場の成長は、慢性疾患や複雑な疾患の有病率の増加、技術の進歩、個別化治療に対する需要の高まりなど、いくつかの要因によってもたらされます。最も重要な要因の1つは、がん治療におけるCAR-Tのような治療の成功です。CAR-Tは、他の治療法を使い果たした患者に持続的かつ効果的な反応をもたらす細胞治療の大きな可能性を実証しました。このため、他の種類のがん、自己免疫疾患、遺伝性疾患への応用拡大を目指した投資や調査が急増しています。特に遺伝子編集とバイオ製造における技術の進歩により、これらの治療法の開発と規模拡大が容易になり、コストの削減とアクセスの改善が進んでいます。幹細胞を用いた治療法は、心不全、糖尿病、神経変性疾患などを治療するために開発されつつあり、市場開発にさらに拍車をかけています。さらに、個別化医療への注目の高まりは、個々の患者に合わせた、より的を絞った効果的な治療選択肢を提供できる細胞治療への需要に拍車をかけています。この動向は、消費者の意識の高まりと、従来の医薬品的アプローチを超えた先進的な最先端治療への欲求によって強化されています。画期的な治療法に対するより迅速な承認経路を含む規制当局の支援も、細胞ベースの治療法の開発と採用を後押ししています。研究、製造能力、規制の枠組みにおける継続的な進歩により、細胞治療市場は今後数年間で持続的な成長を遂げる態勢が整っており、幅広い疾患に対して変革的な治療選択肢を提供します。

セグメント

治療（同種移植、自家移植）;用途（調査、臨床）

調査対象企業の例（全 183件）

  • Anterogen Co., Ltd.
  • Celgene Corporation
  • Cells for Cells S.A.（C4C）
  • Fibrocell Science, Inc.
  • GlaxoSmithKline PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Medipost Co., Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Vericel Corporation

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP10952

Global Cell Therapy Market to Reach US$42.1 Billion by 2030

The global market for Cell Therapy estimated at US$19.1 Billion in the year 2024, is expected to reach US$42.1 Billion by 2030, growing at a CAGR of 14.1% over the analysis period 2024-2030. Allogenic Cell Therapy, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$23.4 Billion by the end of the analysis period. Growth in the Autologous Cell Therapy segment is estimated at 15.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.3 Billion While China is Forecast to Grow at 13.5% CAGR

The Cell Therapy market in the U.S. is estimated at US$5.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 13.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.1% and 11.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.

Global Cell Therapy Market - Key Trends and Drivers Summarized

What Makes Cell Therapy a Game-Changer in Modern Medicine?

Cell therapy is dramatically reshaping the medical field by using the body’s own cells to treat and repair damaged tissues, providing innovative solutions for a wide array of diseases, including cancer, autoimmune disorders, and degenerative conditions. Unlike traditional treatments that often focus on managing symptoms, cell therapy aims to address the root cause of diseases by harnessing living cells that can be engineered or harvested to target specific biological mechanisms. For instance, CAR-T cell therapy has been a breakthrough in oncology, where a patient’s T cells are genetically engineered to seek out and destroy cancer cells. This form of therapy has already shown remarkable success in treating certain types of blood cancers and is expanding into other cancer types. In regenerative medicine, stem cell therapy is being used to repair tissues damaged by heart disease, neurodegenerative disorders, and diabetes. These therapies represent a significant leap forward in personalized treatment, offering hope for patients with diseases that were once considered untreatable. As research progresses, cell therapy is becoming a central pillar in the future of personalized medicine, offering tailored treatments that align with a patient’s unique genetic and cellular makeup.

How Is Cell Therapy Changing the Way Complex Diseases Are Treated?

Cell therapy is crucial for treating complex diseases that do not respond well to traditional treatments, offering new avenues for therapeutic intervention. In the field of oncology, cell-based treatments like CAR-T therapy have revolutionized cancer treatment by using a patient’s own immune cells to target and kill cancerous cells. This highly personalized approach to therapy has shown great success in treating cancers such as leukemia and lymphoma, especially in patients who have not responded to conventional chemotherapy or radiation. Beyond oncology, cell therapy is making strides in managing autoimmune diseases like multiple sclerosis and rheumatoid arthritis, where it helps to modulate and reprogram the immune system, reducing harmful inflammatory responses. In regenerative medicine, stem cell therapies are being developed to restore function to damaged tissues, offering potential cures for conditions like heart failure, spinal cord injuries, and neurodegenerative diseases. These therapies not only aim to repair tissues but also to provide long-term, possibly permanent, solutions by addressing the underlying cellular deficiencies that cause disease. Cell therapy’s ability to replace or restore damaged tissues at a cellular level, rather than merely treating symptoms, makes it a game-changer for complex, chronic, and previously untreatable diseases.

How Are Technological Advances Driving Innovation in Cell Therapy?

Technological advancements are rapidly accelerating progress in cell therapy, making it more effective, scalable, and accessible for a variety of diseases. One of the most transformative technologies has been gene editing, particularly with CRISPR-Cas9, which allows for precise modifications of cells to enhance their therapeutic potential. This has revolutionized CAR-T therapies, enabling scientists to engineer T cells that are highly effective at targeting specific cancer cells, while reducing potential side effects. Beyond genetic engineering, advancements in bioprocessing and automation are making it possible to produce large quantities of therapeutic cells in a controlled environment, which is critical as these therapies move from clinical trials to wider market availability. Additionally, improvements in cryopreservation have made it easier to store and transport therapeutic cells, maintaining their viability across long distances and extended periods, which has helped expand the reach of these treatments to more regions globally. Furthermore, artificial intelligence (AI) and machine learning are being integrated into cell therapy development, helping to optimize the manufacturing process, predict patient responses, and improve treatment outcomes. These technological breakthroughs are not only enhancing the precision and efficiency of cell therapies but are also broadening their applications to treat a wider range of diseases, from rare genetic disorders to age-related conditions.

What Factors Are Propelling the Growth of the Cell Therapy Market?

The growth in the cell therapy market is driven by several factors, including the increasing prevalence of chronic and complex diseases, technological advancements, and the rising demand for personalized treatments. One of the most significant drivers is the success of therapies like CAR-T in cancer treatment, which has demonstrated the immense potential of cell therapies to provide durable and effective responses in patients who have exhausted other treatment options. This has led to a surge in investment and research aimed at expanding cell therapy applications to other types of cancer, autoimmune diseases, and genetic disorders. Technological advancements, particularly in gene editing and biomanufacturing, are making it easier to develop and scale these therapies, driving down costs and improving access. The field of regenerative medicine is another major contributor, as therapies using stem cells are increasingly being developed to treat diseases such as heart failure, diabetes, and neurodegenerative disorders, further fueling market growth. Additionally, the growing focus on personalized medicine is spurring demand for cell therapies that can be tailored to individual patients, offering more targeted and effective treatment options. This trend is reinforced by increasing consumer awareness and the desire for advanced, cutting-edge therapies that go beyond traditional pharmaceutical approaches. Regulatory support, including faster approval pathways for breakthrough therapies, is also encouraging the development and adoption of cell-based treatments. With continuous advancements in research, manufacturing capabilities, and regulatory frameworks, the cell therapy market is poised for sustained growth in the coming years, offering transformative treatment options for a wide range of diseases.

SCOPE OF STUDY:

The report analyzes the Cell Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Allogenic, Autologous); Application (Research, Clinical)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 183 Featured) -

  • Anterogen Co., Ltd.
  • Celgene Corporation
  • Cells for Cells S.A. (C4C)
  • Fibrocell Science, Inc.
  • GlaxoSmithKline PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Medipost Co., Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Vericel Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Cell Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Genetic Engineering Propel Growth of Personalized Cell Therapies
    • Rising Incidence of Chronic Diseases Expands Addressable Market for Cell Therapy
    • Increasing Focus on Regenerative Medicine Strengthens Business Case for Stem Cell Therapies
    • Favorable Regulatory Approvals Accelerate Demand for CAR-T Cell Therapies
    • Expanding Clinical Applications of Cell Therapy Spurs Growth in Cancer Treatment Segments
    • Advances in CRISPR Technology Throws the Spotlight on Gene-Edited Cell Therapies
    • Shift Toward Allogeneic Therapies Expands Market Accessibility and Reduces Costs
    • Rising Awareness of the Benefits of Cell-Based Immunotherapies Drives Patient Demand
    • Innovations in Cryopreservation Strengthen Supply Chain and Logistics for Cell Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Allogenic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Allogenic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Allogenic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Cell Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • JAPAN
    • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • CHINA
    • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • EUROPE
    • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: France 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • GERMANY
    • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Germany 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Italy 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: UK 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Rest of Europe 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Asia-Pacific 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of World 15-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of World 15-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2015, 2025 & 2030

IV. COMPETITION